Clinical trial

Aflibercept in Combination With Docetaxel in Metastatic Androgen Independent Prostate Cancer

NCT00519285

StatusCOMPLETED

Study typeINTERVENTIONAL

Start date2007-08-01

PhasePHASE3

Study timeline

Study start (unknown)2007-08-01Date precision: month

Registry last updated2016-07-22

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Prostatic Neoplasmsunresolved

Neoplasm Metastasisunresolved

Interventions

AfliberceptDRUG · verified · RxNorm: aflibercept

Placebo (for aflibercept)DRUG

DocetaxelDRUG · verified · RxNorm: docetaxel

Prednisone or PrednisoloneDRUG

Sponsors & collaborators

Sanofilead sponsor

Regeneron Pharmaceuticalscollaborator

Mapped research locations

SeoulSouth Korea1 BarcelonaSpain1 ParisFrance1 MilanItaly1 TaipeiTaiwan1 MoscowRussia1 WarsawPoland1 BudapestHungary1 PragueCzechia1 IstanbulTurkey (Türkiye)1 Buenos AiresArgentina1 São PauloBrazil1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT00519285 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.